19Nov 2022
The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis

The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis

To study the longitudinal effects of glucocorticoids (GCs) and tocilizumab, an IL‐6 receptor inhibitor, on haemoglobin A1c (HbA1c) during GC tapering. In 209 patients, the median HbA1c decreased by 0.50% (p<0.01) in the tocilizumab/GC group and by 0.10% (p<0.01) in the GC‐only group. Tocilizumab treatment was associated with a substantial reduction in HbA1c, independent of GC exposure, which may be achieved through a combination of glycemic and non‐glycemic effects.

  • #orthopaedics

Like

Save

Share